S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Modern Day Options Trading For Beginners! (Ad)pixel
Intensity and insults rise as lawmakers debate debt ceiling
UK travelers face hours-long waits for ferries to France
Modern Day Options Trading For Beginners! (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Modern Day Options Trading For Beginners! (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Modern Day Options Trading For Beginners! (Ad)pixel
Intensity and insults rise as lawmakers debate debt ceiling
UK travelers face hours-long waits for ferries to France
Modern Day Options Trading For Beginners! (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Modern Day Options Trading For Beginners! (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Modern Day Options Trading For Beginners! (Ad)pixel
Intensity and insults rise as lawmakers debate debt ceiling
UK travelers face hours-long waits for ferries to France
Modern Day Options Trading For Beginners! (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Modern Day Options Trading For Beginners! (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Modern Day Options Trading For Beginners! (Ad)pixel
Intensity and insults rise as lawmakers debate debt ceiling
UK travelers face hours-long waits for ferries to France
Modern Day Options Trading For Beginners! (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Modern Day Options Trading For Beginners! (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
NASDAQ:LNTH

Lantheus - LNTH Competitors

$82.56
+1.84 (+2.28%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$81.25
$82.71
50-Day Range
$54.59
$82.86
52-Week Range
$47.46
$87.47
Volume
1.13 million shs
Average Volume
1.09 million shs
Market Capitalization
$5.58 billion
P/E Ratio
242.82
Dividend Yield
N/A
Price Target
$107.33

LNTH vs. QDEL, NEOG, NTLA, MYGN, CLDX, ITCI, GMED, RXDX, EHC, and HALO

Should you be buying Lantheus stock or one of its competitors? The main competitors of Lantheus include QuidelOrtho (QDEL), Neogen (NEOG), Intellia Therapeutics (NTLA), Myriad Genetics (MYGN), Celldex Therapeutics (CLDX), Intra-Cellular Therapies (ITCI), Globus Medical (GMED), Prometheus Biosciences (RXDX), Encompass Health (EHC), and Halozyme Therapeutics (HALO). These companies are all part of the "medical" sector.

Lantheus vs.

Lantheus (NASDAQ:LNTH) and QuidelOrtho (NASDAQ:QDEL) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, community ranking, media sentiment, analyst recommendations, profitability and dividends.

97.6% of Lantheus shares are owned by institutional investors. Comparatively, 95.2% of QuidelOrtho shares are owned by institutional investors. 1.6% of Lantheus shares are owned by company insiders. Comparatively, 2.7% of QuidelOrtho shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

QuidelOrtho received 122 more outperform votes than Lantheus when rated by MarketBeat users. Likewise, 67.77% of users gave QuidelOrtho an outperform vote while only 65.61% of users gave Lantheus an outperform vote.

CompanyUnderperformOutperform
LantheusOutperform Votes
309
65.61%
Underperform Votes
162
34.39%
QuidelOrthoOutperform Votes
431
67.77%
Underperform Votes
205
32.23%

QuidelOrtho has a net margin of 16.80% compared to Lantheus' net margin of 3.00%. Lantheus' return on equity of 51.60% beat QuidelOrtho's return on equity.

Company Net Margins Return on Equity Return on Assets
Lantheus 3.00% 51.60% 25.64%
QuidelOrtho 16.80% 20.45% 11.86%

In the previous week, Lantheus had 3 more articles in the media than QuidelOrtho. MarketBeat recorded 8 mentions for Lantheus and 5 mentions for QuidelOrtho. QuidelOrtho's average media sentiment score of 0.86 beat Lantheus' score of 0.03 indicating that QuidelOrtho is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lantheus
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
QuidelOrtho
5 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Lantheus has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500. Comparatively, QuidelOrtho has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500.

QuidelOrtho has higher revenue and earnings than Lantheus. QuidelOrtho is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lantheus$935.06 million5.96$28.07 million$0.34242.82
QuidelOrtho$3.27 billion1.81$548.70 million$12.407.18

Lantheus presently has a consensus target price of $107.33, suggesting a potential upside of 30.01%. QuidelOrtho has a consensus target price of $123.83, suggesting a potential upside of 39.00%. Given QuidelOrtho's higher possible upside, analysts plainly believe QuidelOrtho is more favorable than Lantheus.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lantheus
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
QuidelOrtho
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.80

Summary

QuidelOrtho beats Lantheus on 10 of the 19 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LNTH vs. The Competition

MetricLantheusDiagnostic substances IndustryMedical SectorNASDAQ Exchange
Market Cap$5.58B$2.12B$4.46B$6.04B
Dividend YieldN/A0.85%2.32%5.45%
P/E Ratio242.8240.16102.8314.40
Price / Sales5.961,779.163,593.6771.41
Price / Cash16.7637.0629.0367.28
Price / Book12.708.624.625.04
Net Income$28.07M$24.17M$115.14M$191.92M
7 Day Performance1.39%1.56%1.30%2.30%
1 Month Performance12.97%-7.36%-5.97%-4.65%
1 Year Performance41.47%-35.65%-14.67%-16.31%

Lantheus Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
QDEL
QuidelOrtho
2.6939 of 5 stars
$87.86
+0.5%
$123.83
+40.9%
-20.8%$5.84B$3.27B7.097,000
NEOG
Neogen
1.1078 of 5 stars
$18.49
+1.3%
$20.00
+8.2%
-39.9%$3.95B$630.72M369.801,039Earnings Report
Analyst Upgrade
Options Volume
Analyst Revision
News Coverage
NTLA
Intellia Therapeutics
2.5041 of 5 stars
$37.56
+4.3%
$87.18
+132.1%
-48.7%$3.31B$52.12M-6.08485Analyst Report
News Coverage
MYGN
Myriad Genetics
1.7372 of 5 stars
$23.33
+2.3%
$26.20
+12.3%
-7.8%$1.89B$678.40M-16.782,600Insider Selling
News Coverage
CLDX
Celldex Therapeutics
1.5974 of 5 stars
$35.96
+3.4%
$66.67
+85.4%
+5.6%$1.70B$2.36M-15.05132Short Interest ↑
ITCI
Intra-Cellular Therapies
2.8575 of 5 stars
$56.99
+2.3%
$71.92
+26.2%
-11.5%$5.43B$250.31M-20.95512Analyst Report
Insider Selling
Short Interest ↓
News Coverage
GMED
Globus Medical
2.9076 of 5 stars
$53.47
+0.5%
$70.91
+32.6%
-23.2%$5.36B$759.12M28.752,600Analyst Report
Short Interest ↑
News Coverage
RXDX
Prometheus Biosciences
1.508 of 5 stars
$111.29
+1.5%
$136.70
+22.8%
+184.2%$5.29B$6.81M-31.9872News Coverage
EHC
Encompass Health
3.6394 of 5 stars
$52.61
0.0%
$69.00
+31.2%
-23.9%$5.25B$4.35B19.4935,000Short Interest ↓
HALO
Halozyme Therapeutics
3.4334 of 5 stars
$38.19
+4.6%
$56.13
+47.0%
-4.2%$5.17B$660.12M26.34145
This page (NASDAQ:LNTH) was last updated on 4/1/2023 by MarketBeat.com Staff